GlassScriptPhysician profile
Emily B Hill
NPI 1124536396
$2,636.07
in general payments reported to CMS, 2019-2025
23 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $12.40 · 2023: $448 · 2024: $671 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854 · Travel and Lodging: $375 · Education: $13.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.39 |
| Travel and Lodging | $374.53 |
| Education | $13.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.42 | 2022-2024 | |
| Biosense Webster, INC. | $417.36 | 2025 | Carto 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.25 | 2021 | |
| Abbott Laboratories | $204.68 | 2025 | Ensite, Jot Dx, Assurity |
| Pfizer INC. | $200.14 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.42 | 2021-2025 | Eliquis |
| Medtronic, INC. | $137.95 | 2025 | Selectsecure, Linq II, Cobalt Dr Mri Surescan |
| Genzyme Corporation | $129.08 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $119.43 | 2023-2024 | Linzess |
| Amgen INC. | $97.38 | 2024-2025 | Repatha, Repatha |
| Ardelyx, INC. | $64.19 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $56.73 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $51.32 | 2023 | Dupixent |
| Scpharmaceuticals INC. | $50.21 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.25 | 2023 | Entyvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $46.85 | 2023 | Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.87 | 2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $30.97 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.14 | 2025 | Farxiga |
| Celgene Corporation | $19.83 | 2024 | Zeposia |
| Teleflex LLC | $19.59 | 2025 | Guideliner |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.59 | 2025 | Lifevest |
| Aimmune Therapeutics, INC. | $14.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.